Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Equity Insider News Commentary ? November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

Valinor, a pioneering AI company leveraging advanced machine learning models to increase the probability of clinical trial success by deeply understanding patient response, today announced $13 million ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Plume is bringing real-world yield to Solana with the rollout of its Nest vaults, giving the network’s users direct access to ...

Instead of a single, massive LLM, Nvidia's new 'orchestration' paradigm uses a small model to intelligently delegate tasks to ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Previously, we watched Tim Berners-Lee knit the world together with the Web, giving us pages to browse and links to click. But a web of information is ...